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Objective: To analyze the surgical outcomes and diaphragmatic involvement in stage III and 
IV ovarian cancer.
Patients and methods: All patients with stage III–IV ovarian cancer between January 2013 
and January 2016 were included. The outcomes of interest reviewed were as follows: surgical 
(complications, mortality), peritoneal carcinomatosis index (PCI), rate of complete resection, 
and disease-free interval and survival.
Results: Fifty-seven patients were included, 38 (67%) with diaphragmatic involvement; in 
10 cases (18%), diaphragmatic resection was required. Optimal cytoreduction (OCR) was 
obtained in 49 cases (86%). The PCI was .10 in 31 cases (54%). Respiratory complications 
occurred in 10 cases (18%) and mortality in 3 (5%). Disease-free survival rate in 3 years was 
53%, being 87% in cases without diaphragmatic involvement. The overall survival rate in 3 years 
is 46%, 83% in the cases without diaphragmatic involvement and 27% in cases with affecta-
tion (p,0.05). In cases of OCR, 3 year survival rate was 65%. In the multivariate analysis for 
the overall survival of cases with OCR, the only independent prognostic factor found was the 
operative PCI. A strong correlation was found between the total PCI and the diaphragmatic 
PCI (p,0.001). With a PCI .10, virtually all cases will present diaphragmatic involvement 
(p,0.05).
Conclusion: The tumor burden is different in stages III and IV of advanced ovarian cancer and 
the PCI is an effective method to quantify it. The PCI constitutes an independent prognostic 
factor for the advanced stages of ovarian cancer. A PCI .10 constitutes a useful prognostic 
factor of the affectation and forces the surgeon to thoroughly review both diaphragms.
Keywords: advanced ovarian cancer, peritoneal cancer index, diaphragmatic involvement, 
upper abdominal surgery, carcinomatosis
Introduction
Ovarian cancer in its early stages is asymptomatic, which explains why its early 
detection is uncommon. Thus, most of the cases are diagnosed in advanced stages (III 
and IV) of the International Federation of Gynecology and Obstetrics (FIGO) staging, 
turning it into a cancer with a low survival and a high mortality rate.1
Numerous studies on prognostic factors have shown the clear benefit of cytore-
ductive surgery (CR) in these patients, and optimal debulking with no macroscopic 
evidence of residual tumor is associated with better overall survival in the event of 
disease spread throughout the peritoneal cavity.2
The series published regarding debulking or CR in advanced ovarian cancer dem-
onstrate percentages of cytoreduction ranging between 15% and 85%. In most of these 
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publications, when the percentage of optimal cytoreduction is 
situated above 50%, surgical techniques aimed at debulking 
the upper abdomen, especially the diaphragm, are applied.3,4
The aim of this study is to describe the techniques used for 
diaphragmatic cytoreduction and the prognostic value of the 
quantification of the PCI, in patients with advanced ovarian 
cancer and important diaphragmatic involvement, in a tertiary 
referral hospital for patients with gynecological cancer.
Patients and methods
From January 2013 to January 2016, a total of 57 patients 
with advanced ovarian epithelial cancer were eligible for 
primary debulking surgery and treated in the Multidis-
ciplinary Unit for Abdomino-Pelvic Oncology Surgery 
(MUAPOS) at the University General Hospital of Castellón. 
All interventions were performed by the same surgical team. 
Written informed consent was provided by the patients and 
the study was approved by Ethics and Clinical Research 
Committee of our institution.
The classification of the World Health Organization was 
used for the histological classification.5 The histological 
grade was evaluated according to the criteria of Day et al.6 
The staging was determined according to the system of the 
FIGO.7 All patients received a mechanical bowel prepara-
tion (Citrafleet®; Casen Recordati, Zaragoza, Spain) the 
day before the intervention. Standard antibiotic prophylaxis 
was carried out with metronidazole 1,500 mg IV and gen-
tamycin 240 mg on the day of the intervention; in addition 
to the 2 g of amoxicillin-clavulanic acid IV, which was 
administered 2 hours prior to surgery. Low-molecular-
weight heparin, at a standard dose, was administered as 
thromboembolic prophylaxis, and later continued during 
the postoperative period. Compression stockings were 
also used until the patient was ambulating adequately.
All surgeries were carried out under general anesthesia 
and the abdominal cavity was accessed using a midline xifo-
pubic laparotomy. Sugarbaker’s Peritoneal Carcinomatosis 
Index (PCI) was calculated in all patients at the beginning 
of surgery.8 The scope of the CR surgery carried out in these 
patients, with the aim of obtaining an optimal cytoreduc-
tion (OCR), was related to the spread of the disease and 
included partial or total resection of the organs affected by 
the peritoneal dissemination, which is typical of this disease. 
A peritonectomy of all of the affected peritoneal surfaces, 
including pelvic and paracolic gutters and abdominal anterior 
wall, was performed when macroscopic affectation was found. 
In addition to the basic CR, a diaphragmatic peritonectomy 
and/or resection was performed in some patients presenting 
diaphragmatic involvement. On the right side, the diaphrag-
matic stripping procedure, undertaken in our unit, includes 
the full mobilization of the right hepatic lobe, permitting a 
correct display of the diaphragmatic peritoneum, followed by 
the diaphragmatic peritonectomy, which was performed under 
a better field of vision (Figure 1). In cases of full-thickness 
diaphragmatic resection, the diaphragm is reconstructed 
using interrupted sutures of long-lasting absorbable suture 
material (Figure 2). A “bubble test” was conducted simul-
taneously using thoracic hyperpressure maneuvers to verify 
the effectiveness of the chest closure. A chest tube was not 
systematically used. All patients underwent chest radiographic 
controls in the immediate postoperative period to confirm the 
absence of pneumothorax or pleural effusion.
OCR was defined as residual tumor ,1 cm, complete 
cytoreduction (CCR) as microscopic tumor residue, and 
suboptimal cytoreductive surgery as a residual tumor .1 cm 
in diameter. The complications were classified according 
to the Clavien–Dindo classification;9 only the moderately 
severe high (grade II and III) degrees were taken into account. 
Respiratory complications included respiratory failure, which 
required intubation and assisted ventilation; pneumothorax, 
pneumonia, and pleural effusion, this one needing postop-
erative drainage. Postoperative mortality was defined as the 
patient’s demise within 30 days of surgery and during their 
hospital admission. The patients were discharged when oral 
tolerance was achieved, when both bowel and bladder func-
tion had recovered.
Categorical variables are described by the count and rela-
tive percentage. Quantitative variables are described by the 
median and range (minimum–maximum). Mann–Whitney test 
was used to compare groups of quantitative variables while 
the Fisher’s exact test was used to compare groups of cat-
egorical variables. Correlation between quantitative variables 
Figure 1 Diaphragmatic peritonectomy.
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was analyzed using the Spearman rho coefficient. Kaplan–
Meier method was used for survival univariate analysis, 
along with log-rank test for group comparison. Cox’ regres-
sion was used for survival multivariate analysis. Receiver 
operating characteristic (ROC) curve was used to discrimi-
nate between different diagnostic methods. The statistical 
analysis was conducted using IBM-SPSS package version 22.
Results
The analysis of the 57 patients diagnosed with advanced ovar-
ian cancer and treated in the MUAPOS unit shows a median 
follow-up of 12 months (10–50). The relationship among the 
FIGO stages was the following: one had stage IIIA, another 
had stage IIIB, 36 patients had stage IIIC, and 19 patients 
stage IV. Regarding the diaphragmatic affectation, the 
series of cases is divided into 2 parts: 38 cases presented 
diaphragmatic involvement (67%), 10 (18%) of these cases 
also required a diaphragmatic resection to achieve OCR. 
The main characteristics of these patients are summarized 
in Tables 1 and 2.
In 47 cases (83%), a pelvic and aortocava lymph-
adenectomy was performed with a median of 25 lymph 
nodes analyzed (4–88), and a median of 2 positive lymph 
nodes (0–36). The CCR was reached in 49 cases (86%), 
Figure 2 Diaphragmatic reconstruction post-resection.
Note: Diaphragm is reconstructed using interrupted sutures of long-lasting absorbable suture material. Before closing diaphragm (A) and after (B).
Table 1 Diaphragmatic involvement
Yes (n=38) No (n=19) Total (n=57)
age (years) 60 (41–78) 66 (42–78) 61 (41–78)
ca-125 262 (27–14,125) 80 (23–15,166) 174 (23–15,166)
Operative Pci 15 (3–33) 3 (0–18) 12 (0–33)
categorized operative Pci*
0–10
11–20
.20
8 (21%)
19 (50%)
11 (29%)
18 (95%)
1 (5%)
0
26 (46%)
20 (35%)
11 (19%)
categorized operative Pci*
#10
.10
8 (21%)
30 (79%)
18 (95%)
1 (5%)
26 (46%)
31 (54%)
ascites 10 (26%) 4 (21%) 14 (25%)
complications
Total
clavien–Dindo i–ii
clavien–Dindo iii
clavien–Dindo iV
21 (55%)
10 (47%)
6 (28%)
5 (24%)
8 (42%)
6 (75%)
2 (25%)
0
29 (51%)
16 (55%)
8 (28%)
5 (17%)
respiratory complications* 10 (26%) 0 10 (18%)
Visceral resections* 38 (100%) 10 (53%) 48 (84%)
Diaphragmatic resection* 10 (26%) 0 10 (18%)
splenectomy* 18 (47%) 0 18 (32%)
exitus 90 days 3 (8%) 0 3 (5%)
Disease-free survival at 3 years* 0.3 0.87 0.53
Overall survival at 3 years* 0.27 0.83 0.46
Note: Median (range); count (%); *p,0.05.
Abbreviations: ca, cancer antigen; Pci, peritoneal cancer index.
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OCR in 53 cases (93%), and an suboptimal cytoreductive 
surgery was obtained in 4 cases (7%). The PCI was .10 in 
31 cases (54%), 30 of them with diaphragmatic involvement 
(79%), and 9 (90%) with diaphragmatic resection. A total 
of 18 (32%) splenectomies were performed, all of them in 
cases of diaphragmatic involvement.
From the total number of complications that occurred 
in our series, 10 cases were respiratory (18%), which took 
place in cases of diaphragmatic affectation. Three post-
operative deaths occurred (5%), the 3 of them being patients 
with diaphragmatic involvement, and 2 of them underwent 
diaphragmatic resection. However, such outcomes were not 
directly related to the diaphragmatic surgery.
Disease-free survival rate in 3 years for the entire series 
was 53%, being 87% in cases without diaphragmatic involve-
ment and 30% in those cases with affectation. The overall 
survival rate within 3 years was 46%, 83% in the cases 
without diaphragmatic involvement and 27% in cases with 
affectation (p,0.05; Figure 3). When diaphragmatic resec-
tion was performed, there were no survivors within the 3-year 
time, whereas in the patients without diaphragmatic resection, 
the overall survival was 58% (p,0.05). When an OCC is 
not obtained, there were no survivors beyond 26 months. On 
the other hand, in cases of OCC, survival within 3 years was 
65%, although the difference was not statistically significant 
because there were only 4 cases of suboptimal cytoreduction. 
In the multivariate analysis for the overall survival of cases 
with OCC, the only independent prognostic factor found was 
the operative PCI.
A strong correlation was found between the total PCI 
and the diaphragmatic PCI, being this one highly statistically 
significant (Spearman r=86%, p,0.001). The prognosis 
of diaphragmatic involvement and resection was strongly 
correlated with the PCI (Figures 4 and 5). For a PCI .10, 
there was only 1 case of false positive diaphragmatic involve-
ment (specificity of 95%), with a probability of correct 
Table 2 Diaphragmatic resection
Yes (n=10) No (n=47) Total (n=57)
age (years) 60 (41–74) 63 (41–78) 61 (41–78)
ca-125 197 (41–5,688) 166 (23–15,166) 174 (23–15,166)
Operative Pci* 20 (10–33) 10 (0–33) 12 (0–33)
categorized operative Pci*
#10
.10
1 (10%)
9 (90%)
25 (53%)
22 (47%)
26 (46%)
31 (54%)
Diaphragmatic Pci* 4 (2–6) 1 (0–6) 2 (0–6)
ascites 3 (30%) 11 (23%) 14 (25%)
complications
Total
clavien–Dindo i–ii
clavien–Dindo iii
clavien–Dindo iV
7 (70%)
4 (57%)
2 (29%)
1 (14%)
22 (47%)
12 (55%)
6 (27%)
4 (18%)
29 (51%)
16 (55%)
8 (28%)
5 (17%)
respiratory complications* 4 (40%) 6 (12%) 10 (18%)
exitus 90 days 3 (30%) 0 3 (5%)
Disease-free survival at 3 years* 0.42 0.59 0.53
Overall survival at 3 years* 0 0.58 0.46
Note: Median (range); count (%); *p,0.05.
Abbreviations: ca, cancer antigen; Pci, peritoneal cancer index.
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Figure 3 Diaphragmatic involvement: overall survival.
Notes: Diaphragmatic involvement: 38 cases. Without diaphragmatic involvement: 
19 cases.
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discrimination between affectation and non-affectation 
of 87% (ROC area). Regarding the prognosis of surgical 
resection, for a PCI .10, only 1 case of false negative of 
resection result was observed (sensitivity of 90%) with a high 
probability of correct discrimination between resection and 
non-resection (72%). This means that with a PCI .10, all 
cases will virtually present diaphragmatic involvement, while 
in cases of PCI ,10, the need for a diaphragmatic resection 
is highly unlikely.
Discussion
We present a retrospective series of 57 patients treated in 
our hospital due to advanced ovarian cancer, FIGO stages III 
and IV. Primary debulking surgery followed by postoperative 
chemotherapy is the gold standard in the treatment of 
advanced ovarian cancer. In recent years, the residual tumor 
volume has been associated with survival in such a way that 
after CCR (without macroscopic tumor residue) or after OCR 
(,1 cm of residual tumor), there are benefits in terms of 
survival, unlike the suboptimal or incomplete cytoreduction 
(residual tumor .1 cm).10 In our series, a CCR was achieved 
in 49 cases (86%) and in 4 cases (7%) there was ,1 cm of 
residual tumor. In order to achieve these results, we had to 
apply cytoreduction techniques of the upper abdomen in over 
60% of our cases. These results are similar to those found 
in other series where the spread of the diaphragmatic tumor 
appears in more than 40% of advanced ovarian cancers.11 
In order to achieve a high percentage of OCR, the oncologic 
gynecologists must acquire the necessary skills for upper 
abdominal surgery.12
The median of the PCI measured in the surgical 
exploration in cases of diaphragmatic involvement (PCI=15) 
and in cases of resection (PCI=20) presented a large statisti-
cally significant difference, unlike the cases without involve-
ment (PCI=3) and without resection (PCI=10). PCI was .10 
in 79% of cases of diaphragmatic affectation and in 90% of 
diaphragmatic resection; PCI ,10 was in 95% of patients 
without affectation and in 53% of patients without resection; 
these results were also statistically significant. Along with 
other authors,13 we believe that the amount of tumor in the 
upper abdomen is conditioned by the aggressive biology 
of the tumor (type 2 ovarian tumors in the carcinogenic 
models)14 and possibly by the evolution of the disease during 
a large period of time. Although we have neither a variable 
that can adequately measure the biological aggressiveness 
of the tumor nor the exact time of evolution, these 2 factors 
may probably have repercussions over the PCI value, which 
would act as a surrogate variable with a strong correlation 
with survival. The strong correlation between the total PCI 
and the diaphragmatic PCI suggests that the diaphragmatic 
affectation is merely a marker for the extension of the peri-
toneal disease.
Significant respiratory complications appeared in 10 cases 
(18%), which were much more frequent in those with dia-
phragmatic involvement and resection. In contrast to other 
series, our data revealed that respiratory complications were 
more frequent in cases in which a resection was carried out 
(40%), instead of those in which only a diaphragmatic peri-
tonectomy was performed (26%). Visceral resections, such as 
splenectomy, were carried out in all cases of diaphragmatic 
affectation. As in other series, a high tumor burden forces 
us to perform multiple visceral resections and in cases of 
affectation of the left diaphragm, the splenic disease is very 
frequent.15 The total postoperative mortality within 90 days 
for our series is 5%, all of them with diaphragmatic disease.
The disease-free survival and overall survival within 
3 years were significantly better in the cases without dia-
phragmatic involvement; this fact was associated with a 
?? ????????????
Figure 4 Diaphragmatic involvement: 10 as the cut-off for the Pci.
Notes: Prevalence of involvement: 67%. Sensitivity: 79% (95% CI: 63–90). Specificity: 
95% (95% ci: 74–99). Positive predictive value: 97%. negative predictive value: 69%. 
Discrimination (receiver operating characteristic area): 87%.
Abbreviation: Pci, peritoneal cancer index.
No Yes
PCI
>10
≤10
(Every symbol represents up to 2 observations)
Figure 5 Diaphragmatic resection: 10 as cut-off for Pci.
Notes: Prevalence of resection: 18%. Sensitivity: 90% (95% CI: 56–99). Specificity: 
53% (95% ci: 38–68). Positive predictive value: 29%. negative predictive value: 
96%. Discrimination (receiver operating characteristic area): 72%.
Abbreviation: Pci, peritoneal cancer index.
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lower peritoneal tumor burden. As previously mentioned, 
we believe that in the cases of diaphragmatic disease, a 
high tumor load is usually associated along with a greater 
biological aggressiveness of the tumor, which severely 
compromises the survival of these patients.13,16 In this 
regard, it is also notable that no patient having undergone 
suboptimal cytoreduction survived much longer than 
2 years compared to the 65% survival in 3 years in the 
cases with OCR, despite the fact that 18% of the latter 
presented a PCI .20. This suggests that the surgical effort 
made in the OCR group may have possibly participated 
in the increase of survival, although we were unable to 
demonstrate this correlation in our current study from a 
statistical point of view.
It has been noted in our series that a cut-off at 10 for the 
intraoperative PCI generates an optimal dividing line about 
the possibility of having to carry out surgical acts on the 
diaphragm with peritonectomy, or associating a resection 
of varying size. This will eventually have an impact on the 
probability of respiratory complications in the postopera-
tive course as well as on the overall survival prognosis. 
One of the limitations of this study is the retrospective 
nature of it and another one could be the intraoperative 
quantification of PCI. From the clinical point of view, the 
next step should be the possibility of quantifying PCI in 
preoperative studies and, therefore, the surgeon could be 
prepared for upper abdominal surgeries when a PCI .10 
was found. And finally, one of the unanswered questions, 
is the necessity of performing diaphragmatic peritonectomy 
even without any macroscopic lesion seen in the intraopera-
tive PCI. Further studies are necessary to evaluate these 
2 considerations.
Conclusion
The tumor load is different for stages III and IV and the 
PCI is an effective method to quantify it, especially in 
the advanced stages of ovarian cancer. The diaphragmatic 
involvement and, above all, the need for resection in order 
to achieve an OCR are highly correlated with the total intra-
operative PCI, which constitutes an independent prognostic 
factor for the advanced stages of ovarian cancer. On the 
other hand, a PCI .10 constitutes a useful prognostic fac-
tor of the affectation and forces the surgeon to thoroughly 
review both diaphragms. To achieve a CCR, in more than 
40% of the cases, the oncology gynecologist will conse-
quently need to apply specific surgical techniques for the 
upper abdomen.
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